Targeting angiogenesis in melanoma

Roberta Ferraldeschi, Paul Lorigan

    Research output: Contribution to journalReview articlepeer-review


    Activation of angiogenesis is a necessary condition for tumor growth and metastatic dissemination of solid tumors. Numerous anti-angiogenic agents for the treatment of melanoma are currently in clinical trials or in development. A number of early-phase clinical trials have been completed and studies investigating combinations of targeted agents or combining treatment with chemotherapy are ongoing. The present review focuses on the most recent developments in the field of angiogenesis targeting in melanoma and provides a brief overview of available clinical data and future directions.
    Original languageEnglish
    Pages (from-to)237-248
    Number of pages12
    JournalExpert Review of Dermatology
    Issue number3
    Publication statusPublished - 14 Sept 2009


    • Angiogenesis
    • Anti-angiogenic agent
    • Melanoma
    • Monoclonal antobody
    • New treatment strategies
    • Protein kinase inhibitor


    Dive into the research topics of 'Targeting angiogenesis in melanoma'. Together they form a unique fingerprint.

    Cite this